GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Short Interest

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Short Interest


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of CERo Therapeutics Holdings's Short Interest

For the Biotechnology subindustry, CERo Therapeutics Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Short Interest falls into.



CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines